OFF-LABEL PROMOTIONS, FDA/INDUSTRY COLLABORATION ON DRUG DEVELOPMENT WILL BE SUBJECT OF SENATE HEARING FEB. 21-22; KASSEBAUM BILL MARK-UP EXPECTED IN MARCH
Executive Summary
Off-label promotion of drugs will be the subject of one of two days of hearings scheduled by Sen. Kassebaum's (R-Kan.) Labor & Human Resources Committee Feb. 21-22.